FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average	burden				
houre per response	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)														
1. Name and Address of Reporting Person *- Baskies Arnold M			2. Issuer Name and Ticker or Trading Symbol Anixa Biosciences Inc [ANIX]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner						
(Last) (First) (Middle) C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250			3. Date of Earliest Transaction (Month/Day/Year) 03/10/2022					_	Officer (give	title below)	Other (specify below)			
SAN JOSE	E,, CA 951	(Street)		4. If Amo	endn	nent, Date	Origi	nal Filed(Mo	onth/Day/Year)		Individual or Form filed by C Form filed by M	ne Reporting Po		licable Line)	
(City)		(State)	(Zip)	Table I - Non-Derivative Securities Acqu					es Acquire	ired, Disposed of, or Beneficially Owned					
1.Title of Sec (Instr. 3)	curity		2. Transaction Date (Month/Day/Year) any	ion	Date, if C	Tranode nstr.	8) (A. Securities Acqual A) or Disposed of Constr. 3, 4 and 5) (A) or (D)	of (D) Ow Tra	Amount of Se rned Followir nsaction(s) str. 3 and 4)		O Fo D or (T	wnership of Be rect (D) Indirect (Ir	Nature Indirect eneficial wnership nstr. 4)
			Table II					in this a curre	s who respond form are not really valid OME osed of, or Bene nvertible securi	equired to 3 control : ficially Ow	respond u number.				74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	xercise (Month/Day/Year) e of ivative	3A. Deemed Execution Date, if r) any (Month/Day/Year)	4. f Transaction Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title an of Underl Securities	7. Title and Amount of Underlying Securities Instr. 3 and 4)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Security: Direct (D) or Indirect (I)	11. Natur of Indirec Beneficia Ownershi (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration e Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Employee Stock Option (Right to Buy) (1)	\$ 2.74	03/10/2022		A		100,000)	(2)	03/10/2032	Commo	ⁿ 100,000	\$ 0	100,000	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Baskies Arnold M C/O ANIXA BIOSCIENCES, INC. 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE,, CA 95118	X					

Signatures

/s/ Arnold M. Baskies	03/11/2022			
**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
- (2) The options vest and become exercisable in twelve (12) equal monthly installments beginning March 31, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.